Joshua Sabari, MD, a thoracic medical oncologist, Perlmutter Cancer Center, NYU Langone Health, discusses actionable mutations in advanced non–small cell lung cancer (NSCLC). KRAS mutations as a whole ...
KRAS was long thought undruggable in cancer until scientists discovered a hidden binding pocket in mutant KRAS, leading to targeted therapies. In this discussion, Asfar S. Azmi, professor at Karmanos ...
KRas, part of a family of proteins commonly mutated in cancer, is one of the most desirable drug targets in the pharmaceutical industry. It is also one of the most maddeningly difficult targets; after ...
The GTPase protein KRAS is commonly mutated in various cancer types, including pancreatic adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small cell lung cancer (NSCLC), occurring in 90%, 40%, ...
Evolutionary divergence in the GTPase (G) domain of RAS isoforms is minimal, with only few non-homologous amino acids present. As such, the ability of the drug to inhibit only a single RAS isoform was ...
Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced clinical benefit from the oral KRAS G12D inhibitor zoldonrasib, according to ...
JCO PO author Dr. Hatim Husain at University of California San Diego, shares insights into his JCO PO article, “Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results